Peringatan Keamanan

Oral LD50 in the rat is 4000 mg/kg and 960 mg/kg in the mouse. Symptoms of overdose include tachycardia, dizziness, dry mouth, behavioral disturbances, uncoordination and drowsiness.

Cyclopentolate

DB00979

small molecule approved

Deskripsi

A parasympatholytic anticholinergic used solely to obtain mydriasis or cycloplegia.

Struktur Molekul 2D

Berat 291.3853
Wujud solid

Peta Jejaring Molekuler
Legenda: Obat • Target • Gen • Enzim • (Panah → menunjukkan arah efek / relasi) • Transporter • Carrier

Profil Farmakokinetik

Waktu Paruh (Half-Life) -
Volume Distribusi -
Klirens (Clearance) -

Absorpsi

Absorbed following ophthalmic administration.

Metabolisme

Data metabolisme tidak tersedia.

Rute Eliminasi

Data eliminasi belum tersedia.

Interaksi Obat

231 Data
Tramadol The risk or severity of adverse effects can be increased when Tramadol is combined with Cyclopentolate.
Trospium The risk or severity of adverse effects can be increased when Trospium is combined with Cyclopentolate.
Oxyphenonium The risk or severity of adverse effects can be increased when Oxyphenonium is combined with Cyclopentolate.
Butabarbital The risk or severity of adverse effects can be increased when Butabarbital is combined with Cyclopentolate.
Butalbital The risk or severity of adverse effects can be increased when Butalbital is combined with Cyclopentolate.
Benzatropine The risk or severity of adverse effects can be increased when Benzatropine is combined with Cyclopentolate.
Ziprasidone The risk or severity of adverse effects can be increased when Ziprasidone is combined with Cyclopentolate.
Disopyramide The risk or severity of adverse effects can be increased when Disopyramide is combined with Cyclopentolate.
Talbutal The risk or severity of adverse effects can be increased when Talbutal is combined with Cyclopentolate.
Pentobarbital The risk or severity of adverse effects can be increased when Pentobarbital is combined with Cyclopentolate.
Amitriptyline The risk or severity of adverse effects can be increased when Amitriptyline is combined with Cyclopentolate.
Ipratropium The risk or severity of adverse effects can be increased when Ipratropium is combined with Cyclopentolate.
Methadone The risk or severity of adverse effects can be increased when Methadone is combined with Cyclopentolate.
Olanzapine The risk or severity of adverse effects can be increased when Olanzapine is combined with Cyclopentolate.
Metixene The risk or severity of adverse effects can be increased when Metixene is combined with Cyclopentolate.
Terfenadine The risk or severity of adverse effects can be increased when Terfenadine is combined with Cyclopentolate.
Buclizine The risk or severity of adverse effects can be increased when Buclizine is combined with Cyclopentolate.
Clozapine The risk or severity of reduced gastrointestinal motility can be increased when Cyclopentolate is combined with Clozapine.
Doxylamine The risk or severity of adverse effects can be increased when Doxylamine is combined with Cyclopentolate.
Trihexyphenidyl The risk or severity of adverse effects can be increased when Trihexyphenidyl is combined with Cyclopentolate.
Oxyphencyclimine The risk or severity of adverse effects can be increased when Oxyphencyclimine is combined with Cyclopentolate.
Procyclidine The risk or severity of adverse effects can be increased when Procyclidine is combined with Cyclopentolate.
Profenamine The risk or severity of adverse effects can be increased when Profenamine is combined with Cyclopentolate.
Metocurine iodide The risk or severity of adverse effects can be increased when Metocurine iodide is combined with Cyclopentolate.
Secobarbital The risk or severity of adverse effects can be increased when Secobarbital is combined with Cyclopentolate.
Promazine The risk or severity of adverse effects can be increased when Promazine is combined with Cyclopentolate.
Hyoscyamine The risk or severity of adverse effects can be increased when Hyoscyamine is combined with Cyclopentolate.
Cyproheptadine The risk or severity of adverse effects can be increased when Cyproheptadine is combined with Cyclopentolate.
Imipramine The risk or severity of adverse effects can be increased when Imipramine is combined with Cyclopentolate.
Methscopolamine bromide The risk or severity of adverse effects can be increased when Methscopolamine bromide is combined with Cyclopentolate.
Metharbital The risk or severity of adverse effects can be increased when Metharbital is combined with Cyclopentolate.
Fluoxetine The risk or severity of adverse effects can be increased when Fluoxetine is combined with Cyclopentolate.
Chlorpromazine The risk or severity of adverse effects can be increased when Chlorpromazine is combined with Cyclopentolate.
Gallamine triethiodide The risk or severity of adverse effects can be increased when Gallamine triethiodide is combined with Cyclopentolate.
Darifenacin The risk or severity of adverse effects can be increased when Darifenacin is combined with Cyclopentolate.
Tridihexethyl The risk or severity of adverse effects can be increased when Tridihexethyl is combined with Cyclopentolate.
Triflupromazine The risk or severity of adverse effects can be increased when Triflupromazine is combined with Cyclopentolate.
Dextromethorphan The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Cyclopentolate.
Anisotropine methylbromide The risk or severity of adverse effects can be increased when Anisotropine methylbromide is combined with Cyclopentolate.
Nortriptyline The risk or severity of adverse effects can be increased when Nortriptyline is combined with Cyclopentolate.
Amoxapine The risk or severity of adverse effects can be increased when Amoxapine is combined with Cyclopentolate.
Cisatracurium The risk or severity of adverse effects can be increased when Cisatracurium is combined with Cyclopentolate.
Atropine The risk or severity of adverse effects can be increased when Atropine is combined with Cyclopentolate.
Thiopental The risk or severity of adverse effects can be increased when Thiopental is combined with Cyclopentolate.
Nicardipine The risk or severity of adverse effects can be increased when Nicardipine is combined with Cyclopentolate.
Mecamylamine The risk or severity of adverse effects can be increased when Mecamylamine is combined with Cyclopentolate.
Pirenzepine The risk or severity of adverse effects can be increased when Pirenzepine is combined with Cyclopentolate.
Paroxetine The risk or severity of adverse effects can be increased when Paroxetine is combined with Cyclopentolate.
Procaine The risk or severity of adverse effects can be increased when Procaine is combined with Cyclopentolate.
Homatropine methylbromide The risk or severity of adverse effects can be increased when Homatropine methylbromide is combined with Cyclopentolate.
Rocuronium The risk or severity of adverse effects can be increased when Rocuronium is combined with Cyclopentolate.
Atracurium besylate The risk or severity of adverse effects can be increased when Atracurium besylate is combined with Cyclopentolate.
Scopolamine The risk or severity of adverse effects can be increased when Scopolamine is combined with Cyclopentolate.
Isoflurane The risk or severity of adverse effects can be increased when Isoflurane is combined with Cyclopentolate.
Benzquinamide The risk or severity of adverse effects can be increased when Benzquinamide is combined with Cyclopentolate.
Clidinium The risk or severity of adverse effects can be increased when Clidinium is combined with Cyclopentolate.
Propiomazine The risk or severity of adverse effects can be increased when Propiomazine is combined with Cyclopentolate.
Propantheline The risk or severity of adverse effects can be increased when Propantheline is combined with Cyclopentolate.
Primidone The risk or severity of adverse effects can be increased when Primidone is combined with Cyclopentolate.
Dicyclomine The risk or severity of adverse effects can be increased when Dicyclomine is combined with Cyclopentolate.
Tropicamide The risk or severity of adverse effects can be increased when Tropicamide is combined with Cyclopentolate.
Biperiden The risk or severity of adverse effects can be increased when Biperiden is combined with Cyclopentolate.
Brompheniramine The risk or severity of adverse effects can be increased when Brompheniramine is combined with Cyclopentolate.
Methylphenobarbital The risk or severity of adverse effects can be increased when Methylphenobarbital is combined with Cyclopentolate.
Cocaine The risk or severity of adverse effects can be increased when Cocaine is combined with Cyclopentolate.
Quinidine The risk or severity of adverse effects can be increased when Quinidine is combined with Cyclopentolate.
Amantadine The risk or severity of adverse effects can be increased when Amantadine is combined with Cyclopentolate.
Maprotiline The risk or severity of adverse effects can be increased when Maprotiline is combined with Cyclopentolate.
Methantheline The risk or severity of adverse effects can be increased when Methantheline is combined with Cyclopentolate.
Hexafluronium The risk or severity of adverse effects can be increased when Hexafluronium is combined with Cyclopentolate.
Cycrimine The risk or severity of adverse effects can be increased when Cycrimine is combined with Cyclopentolate.
Desloratadine The risk or severity of adverse effects can be increased when Desloratadine is combined with Cyclopentolate.
Glycopyrronium The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Glycopyrronium.
Tolterodine The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Tolterodine.
Oxybutynin The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Oxybutynin.
Promethazine The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Promethazine.
Diphenhydramine The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Diphenhydramine.
Pentolinium The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pentolinium.
Trimethaphan The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Trimethaphan.
Doxacurium The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Doxacurium.
Doxepin The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Doxepin.
Flavoxate The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Flavoxate.
Desipramine The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Desipramine.
Orphenadrine The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Orphenadrine.
Phenobarbital The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Phenobarbital.
Escitalopram The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Escitalopram.
Tubocurarine The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Tubocurarine.
Quetiapine The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Quetiapine.
Mivacurium The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Mivacurium.
Levacetylmethadol The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Levacetylmethadol.
Diphenidol The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Diphenidol.
Aripiprazole The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Aripiprazole.
Chlorprothixene The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Chlorprothixene.
Fenoterol The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Fenoterol.
Metocurine The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Metocurine.
Pancuronium The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pancuronium.
Pipecuronium The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Pipecuronium.
Vecuronium The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Vecuronium.
Amobarbital The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Amobarbital.
Aprobarbital The risk or severity of adverse effects can be increased when Cyclopentolate is combined with Aprobarbital.

Target Protein

Muscarinic acetylcholine receptor M1 CHRM1
Muscarinic acetylcholine receptor M5 CHRM5

Referensi & Sumber

Synthesis reference: Treves, G.R.; US. Patent 2,554,511; May 29,1951; assigned to Schieffelin & Co.
Link

Contoh Produk & Brand

Produk: 28 • International brands: 5
Produk
  • Ak-pentolate
    Solution / drops • 10 mg/1mL • Ophthalmic • US • Generic • Approved
  • Cyclogyl
    Solution • 10 mg/1mL • Ophthalmic • US • Generic • Approved
  • Cyclogyl
    Solution • 20 mg/1mL • Ophthalmic • US • Generic • Approved
  • Cyclogyl
    Solution / drops • 5 mg/1mL • Ophthalmic • US • Generic • Approved
  • Cyclogyl
    Solution / drops • 10 mg/1mL • Ophthalmic • US • Generic • Approved
  • Cyclogyl
    Solution / drops • 20 mg/1mL • Ophthalmic • US • Generic • Approved
  • Cyclogyl
    Solution / drops • 1 % w/v • Ophthalmic • Canada • Approved
  • Cyclomydril
    Solution / drops • - • Ophthalmic • US • Generic • Approved
Menampilkan 8 dari 28 produk.
International Brands
  • Bell Pentolate
  • Cylate — Ocusoft
  • Mydrilate — Intrapharm
  • Ocu-Pentolate
  • Pentolair

Sekuens Gen/Protein (FASTA)

Sekuens dimuat saat dibutuhkan agar halaman tetap ringan.
© 2025 Digital Pharmacy Research - Universitas Esa Unggul